CNS Pharmaceuticals, Inc. entered into an employment agreement with Steve O’Loughlin to serve as Chief Financial Officer effective March 2, 2026, and with Christopher Downs to resign as CFO and serve as Senior Vice President – Finance effective the same date. These changes involve new compensation arrangements including base salaries, bonuses, equity grants, and severance terms.
Key takeaways
Steve O’Loughlin appointed CFO effective March 2, 2026, with $450,000 base salary and 40% target bonus
O’Loughlin initial grant of 9,500 RSUs vesting 25% at 6 months, 25% at 12 months, 50% quarterly thereafter
Christopher Downs resigning as CFO to SVP – Finance effective March 2, 2026, with $350,000 base salary and 30% target bonus
O’Loughlin severance: 6 months base salary plus target bonus, prorated bonus, full equity vesting acceleration
Downs severance: 6 months base salary
No family relationships or Item 404 transactions with O’Loughlin